Calithera Reports Financial Results for the Fiscal Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Calithera Reports Financial Results for the Fiscal Quarter Ended September 30, 2014

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA ), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today its financial results for the fiscal quarter ended September 30, 2014.

"Calithera has made significant accomplishments, both financially and operationally, through the third quarter of this year," said Susan Molineaux, PhD, President and Chief Executive Officer. "With the successful completion of our initial public offering following the end of the third quarter, we have strengthened our balance sheet and we continue to execute on our development plan to meet our milestones in 2015."

Selected Third Quarter 2014 Financial Results

Cash and cash equivalents totaled $34.9 million at September 30, 2014. In October 2014, Calithera raised net proceeds of approximately $71.7 million in its initial public offering.

Research and development expenses for the three months ended September 30, 2014 were $3.9 million, compared to $2.7 million in the same period in 2013. The increase in research and development expenses from 2013 to 2014 was primarily attributed to higher expenses associated with the advancement of CB-839, the Company's first-in-class glutaminase inhibitor, into Phase 1 clinical trials in February 2014 and investments in the Company's arginase inhibitors program.

General and administrative expenses for the three months ended September 30, 2014 were $1.3 million, compared to $0.6 million in the same period in 2013. The increase from 2013 to 2014 was primarily due to higher employment related expenses, including stock based compensation expense, and professional service fees relating to the Company's preparations to operate as a publicly traded company.

About Calithera

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera's lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. Calithera is headquartered in South San Francisco. For more information about Calithera, please visit  www.calithera.com .

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Such statements contained in this press release include expectations regarding the timing of initiation and enrollment of our clinical trials. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, as well as risks relating to Calithera's business in general, see Calithera's prospectus dated October 1, 2014, filed with the Securities and Exchange Commission (SEC) on October 2, 2014 and Quarterly Report on Form 10-Q filed with the SEC on November 13, 2014.

Calithera Biosciences, Inc.
Selected Statements of Operations Financial Data
(in thousands)
(unaudited)
  Three Months Ended
September 30,
Nine Months Ended
September 30,
  2014 2013 2014 2013
Operating expenses:        
Research and development  $ 3,894  $ 2,735  $ 11,395  $ 6,804
General and administrative  1,347  583  3,488  1,486
Total operating expenses  5,241  3,318  14,883  8,290
Loss from operations  (5,241)  (3,318)  (14,883)  (8,290)
Other income  2  —  4  —
Net loss and comprehensive loss  $ (5,239)  $ (3,318)  $ (14,879)  $ (8,290)
 
Calithera Biosciences, Inc.
Selected Balance Sheets Financial Data
(in thousands)
(unaudited)
     
  September 30,
2014
December 31,
2013
Balance Sheet Data:    
Cash and cash equivalents  $ 34,852  $ 33,820
Working capital  32,128  32,825
Total assets  39,642  34,844
Accumulated deficit  (45,021)  (30,142)
Total stockholders' (deficit) equity  (35,013)  (20,813)

Jennifer McNealey 650-870-1071

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Telit Cinterion Tests Its Defense Connectivity Pitch

Updated Category News Views 107

Defense connectivity is a messy business, and Telit Cinterion is leaning straight into the mess at NATO Edge 2026 in Izmir, Turkey. From November 17 through 19, the company is using Booth L86 to show how several wireless links can live inside one mission-focused setup. That may sound like standard trade-show wallpaper, but the underlying problem is very real: military and...

Continue Reading
Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 86

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 45

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 121

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 20

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 164

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 112

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 38

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 95

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading

Top 5 Most Recently Viewed Articles

Shell PLC's Strategic Share Repurchase Program Explained

Updated Category News Views 198

Understanding Shell PLC's Share Repurchase Strategy Shell plc has recently made headlines with its ongoing share buyback program. On a notable date, the company announced a significant purchase of its own shares intended for cancellation. This action is a part of its broader strategy to enhance shareholder value and optimize its capital structure. Details of the Share...

Continue Reading
Teck Resources Faces Maintenance Challenges at Chile Operations

Updated Category News Views 255

Maintenance Updates from Teck Resources Limited Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) has recently reported important updates regarding maintenance challenges at its operations in Chile. A mechanical issue has emerged at the Carmen de Andacollo (CdA) site, necessitating a temporary shutdown of the SAG mill. According to the latest information,...

Continue Reading
Neinor Homes Achieves FY24 Targets and New Shareholder Returns

Updated Category News Views 151

Neinor Homes Achieves Fiscal Targets for 2024 In a recent update, Neinor Homes reports successful fulfillment of its Adjusted Net Income target of €65 million for fiscal year 2024. The company, known for its prominence in residential property development, is now poised for continued growth. With the expected announcement of its fiscal results set for the latter part of...

Continue Reading
STG Logistics Staff Earn Supply Chain Accolades

Updated Category News Views 41

There's a fresh breeze running through the corridors of STG Logistics. Why? Because two of their own have snagged some serious recognition with the 2026 Women in Supply Chain Awards. This isn't just another blip on the corporate radar—it's a salute to the powerhouse of leadership and innovation nestled within the company's ranks. Geoff Anderman, the CEO himself, was...

Continue Reading
WISeKey International Holding Ltd Unveils AGM Agenda for Stakeholders

Updated Category News Views 284

WISeKey International Holding Ltd Unveils AGM Agenda for Stakeholders WISeKey International Holding Ltd, recognized for its significant contributions in the fields of cybersecurity and IoT, has announced the essential items for consideration by its shareholders at the upcoming Annual General Meeting (AGM). This important gathering, set to foster engagement between...

Continue Reading